



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/978,243	10/15/2001	Juan-Carlos Diaz	P842 CIP	4113
28390	7590	09/21/2004		
MEDTRONIC VASCULAR, INC. IP LEGAL DEPARTMENT 3576 UNOCAL PLACE SANTA ROSA, CA 95403			EXAMINER THALER, MICHAEL H	
			ART UNIT 3731	PAPER NUMBER

DATE MAILED: 09/21/2004

Please find below and/or attached an Office communication concerning this application or proceeding.

**Office Action Summary**

Application No.

09/978,243

Applicant(s)

DIAZ, JUAN-CARLOS

Examiner

Michael Thaler

Art Unit

3731

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

**Period for Reply**

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

**Status**

- 1) ☒ Responsive to communication(s) filed on 11 June 2004.
- 2a) ☒ This action is **FINAL**. 2b) ☐ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

**Disposition of Claims**

- 4) ☒ Claim(s) 1-27 is/are pending in the application.
- 4a) Of the above claim(s) \_\_\_\_\_ is/are withdrawn from consideration.
- 5) ☒ Claim(s) 21,22 and 25-27 is/are allowed.
- 6) ☒ Claim(s) 1,11,23 and 24 is/are rejected.
- 7) ☒ Claim(s) 2-10 and 12-20 is/are objected to.
- 8) ☐ Claim(s) \_\_\_\_\_ are subject to restriction and/or election requirement.

**Application Papers**

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on \_\_\_\_\_ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.  
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

**Priority under 35 U.S.C. § 119**

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some \* c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
2. ☐ Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.
3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).
- \* See the attached detailed Office action for a list of the certified copies not received.

**Attachment(s)**

- 1) ☐ Notice of References Cited (PTO-892)
- 2) ☐ Notice of Draftperson's Patent Drawing Review (PTO-948)
- 3) ☐ Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)  
Paper No(s)/Mail Date \_\_\_\_\_.
- 4) ☐ Interview Summary (PTO-413)  
Paper No(s)/Mail Date. \_\_\_\_\_.
- 5) ☐ Notice of Informal Patent Application (PTO-152)
- 6) ☐ Other: \_\_\_\_\_.

Art Unit: 3731

Claims 1, 7/1, 8/7/1, 9/1, 10/9/1, 11, 17/11, 18/17/11, 19/11, 20/19/11, 23 and 24 are rejected under 35 U.S.C. 103(a) as being unpatentable over Fiedler (5,817,101) in view of Bartholf et al. (2001/0034549). Fiedler, in figures 1-3, discloses catheter 22 having a guidewire lumen 24 and pressurizing lumen 26, fixed seal mount (the portion of catheter 22 which supports seal 38), sheath 36 having a movable seal mount (the portion of sheath 36 which supports seal 40), a stent retention portion of said sheath (the portion of sheath 36 which surrounds stent 50 prior to stent deployment), a stent retraction portion of said sheath (the proximal portion of sheath 36 which surrounds seal 38 prior to stent deployment), first seal structure 38 and second seal structure 40. Fiedler fails to disclose the stent retraction portion of said sheath being made of a material different from the material of the stent retention portion of said sheath. However, Bartholf et al. teach that a stent containment sheath should include several sections, best shown in figure 3, including a stent retention portion 63 made of a first material (the stainless steel of braiding 77) which has an inner surface which is inherently lubricious and a stent retraction portion made of a second material (the Teflon of layer 69) different from the first material. This arrangement has the apparent advantage of

Art Unit: 3731

providing high strength to the sheath, due to the stainless steel of braiding 77. It would have been obvious to include this arrangement in the Fiedler sheath so that it too would have this advantage. Fiedler fails to disclose a "stent plunger" to provide a backing for the stent. However, Bartholf et al. teach that a stent should be supported or backed by a rigid stop 22 to prevent it from migrating proximally within the sheath during sheath retraction (paragraph [0028]). It would have been obvious to include a rigid stop on the Fiedler catheter 22, separate from flexible seal 38, so that it too would have this advantage. As to claims 8, 10, 18 and 20, Fiedler fails to disclose a backstop to limit the retraction of the sleeve. However, it is old and well known in this art to use a backstop on a stent deployment catheter in order to insure that the sleeve does not retract too far. It would have been obvious to include a backstop on the Fiedler catheter 22 so that it too would have this advantage. As to claims 9, and 19, Fiedler fails to disclose the distal portion of sheath (opposite the stent retention section of catheter 22) as having an inside diameter which is different than the inside diameter of the proximal portion of the sheath (opposite the stent retraction section of catheter 22). However, Bartholf et al. teach that the diameter of the distal portion 44 of a stent deployment

Art Unit: 3731

sheath should be larger than the diameter of its proximal portion in order to minimize the diameter of the proximal portion to provide a large clearance between it and a guiding catheter (paragraph [0032]). It would have been obvious to provide different diameters on the proximal and distal portions of the Fiedler sheath 36 so that it too would have this advantage. As to claim 23, Fiedler fails to disclose the distal portion of sheath as having a wall thickness which is different than the wall thickness of the proximal portion of the sheath. However, it is old and well known in this art to make the distal portion of a stent deployment sheath of a thickness which is smaller than the thickness of its proximal portion in order to facilitate its insertion and advancement through the vasculature. It would have been obvious to make the wall of the distal portion of sheath 36 thinner so that it too would have this advantage. The above well known in the art statements are taken to be admitted prior art because applicant failed to traverse the examiner's assertions (M.P.E.P. 2144.03).

Claims 2-6, 7/(2-6), 8/7/(2-6), 9/(2-6), 10/9/(2-6), 12-16, 17/(12-16), 18/17/(12-16), 19/(12-16) and 20/19/(12-16) are objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including

Art Unit: 3731

all of the limitations of the base claim and any intervening claims.

Claims 21, 22 and 25-27 are allowed.

Applicant's arguments filed June 11, 2004 have been fully considered but they are not persuasive for the reasons set forth above.

THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.


Any inquiry concerning this communication or earlier communications from the examiner should be directed to Michael Thaler whose telephone number is (703) 308-2981. The examiner can normally be reached Monday to Friday.

Art Unit: 3731

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Anhtuan T. Nguyen can be reached on (703)308-2154. The fax phone number for the organization where this application or proceeding is assigned is (703)872-9306.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (703)308-0858.

mht  
9/17/04



MICHAEL THALER  
PRIMARY EXAMINER  
ART UNIT 3731